Sigilon Therapeutics Inc

-0.06 (-7.15%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)25.84M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$2.5 Million
Adjusted EPS-$0.43
See more estimates
10-Day MA$0.88
50-Day MA$1.27
200-Day MA$3.26
See more pivots

Sigilon Therapeutics Inc Stock, NASDAQ:SGTX

100 Binney Street, Suite 600, Cambridge, Massachusetts 02142
United States of America
Phone: +1.617.336.7540
Number of Employees: 66


Sigilon Therapeutics, Inc. is a biopharmaceutical company, which engages in the research and development of therapeutic treatments for a wide range of chronic diseases. Its program includes Rare Blood Disorders, Lysosomal Storage Diseases, and Endocrine and Other Chronic Diseases. The company was founded by Daniel G. Anderson, Robert S. Langer Jr., Jose Oberholzer, Arturo Vegas, and Omid Veiseh on May 14, 2015 and is headquartered in Cambridge, MA.